Device Trial Radar · NCT04044248
TIPS Plus Transvenous Obliteration for Gastric Varices
Last checked: Nov 19, 2026Latest source record: Nov 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Apr 4, 2019
Primary completion
Jun 18, 2024
Study completion Jun 18, 2024
Sponsor
- Lead sponsor
- University of Illinois ChicagoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 5, 2019
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
Variceal hemorrhage (VH) from gastric varices (GVs) results in significant morbidity and mortality among patients with liver cirrhosis. In cases of acute bleeding, refractory bleeding, or high risk GVs, the transjugular intrahepatic portosystemic shunt (TIPS) creation and transvenous variceal obliteration procedures have used to treat GVs. While these techniques are effective, each is associated with limitations, including non-trivial rebleeding and hepatic encephalopathy rates for TIPS and aggravation of esophageal varices, development of new or worsening ascites, and formation of difficult to treat ectopic varices for transvenous obliteration. Increasingly, however, TIPS and transvenous obliteration are viewed as complimentary procedures that can be combined to reduce bleeding risk and ameliorate sequelae of portal hypertension. Yet, despite a strong mechanistic basis for their combination, there are few studies investigating the combined effectiveness of TIPS plus transvenous obliteration. Thus, the aim of this single center prospective pilot study is to assess the effectiveness and safety of combined TIPS creation plus transvenous obliteration for the treatment of GVs, with the overall goal of improving the clinical outcomes of patients with VH related to GVs. The work proposed could lead to important advances in the treatment of bleeding complications due to liver cirrhosis.
Conditions
- Cirrhosis, Liver
- Hypertension, Portal
- Esophageal and Gastric Varices
- Bleeding Gastric
- Encephalopathy
Interventions
TIPS-obliterationDevice
Transjugular intrahepatic portosystemic shunt (TIPS) decompression of portal hypertension coupled with transvenous obliteration of gastric varices (GVs).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Endoscopic gastric varices eradication rateTime frame: 6-months
- Endoscopic esophageal varices aggravation/resolution rateTime frame: 6-months
- Imaging gastric variceseradication rateTime frame: 1-year
2 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Illinois at Chicago
Chicago, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.